ANVS (STOCKS)
Annovis Bio, Inc.
$1.680000
+0.090000 (+5.66%)
Prev close: $1.590000
Company Information
- Exchange
- XNYS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Maria-Luisa Maccecchini
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $47.07M
- Employees
- 6
- P/E (TTM)
- -1.13
- P/B (TTM)
- 2.57
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
2
Strong Buy
7
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$-0.39 | $-0.35 | -0.0398 | -11.36% |
|
Sep 2025 (Q3)
|
$-0.37 | $-0.31 | -0.0589 | -18.93% |
|
Jun 2025 (Q2)
|
$-0.32 | $-0.41 | +0.0906 | +22.07% |
|
Mar 2025 (Q1)
|
$-0.32 | $-0.36 | +0.0435 | +11.97% |
Financial Statements
| Revenues | $0.00 |
| Nonoperating Income/Loss | $841.06K |
| Operating Expenses | $29.70M |
| Research and Development | $25.22M |
| Other Operating Expenses | $4.48M |
| Operating Income/Loss | -$29.70M |
| Income/Loss From Continuing Operations After Tax | -$28.85M |
| Income/Loss From Continuing Operations Before Tax | -$28.85M |
| Income Tax Expense/Benefit | $0.00 |
| Net Income/Loss | -$28.85M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$28.85M |
| Net Income/Loss Available To Common Stockholders, Basic | -$28.85M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$1.40 |
| Diluted Earnings Per Share | -$1.40 |
| Basic Average Shares | 20,551,997 |
| Diluted Average Shares | 20,551,997 |
| Assets | $21.08M |
| Current Assets | $21.08M |
| Noncurrent Assets | $0.00 |
| Liabilities | $4.23M |
| Current Liabilities | $3.64M |
| Accounts Payable | $2.59M |
| Wages | $426.20K |
| Other Current Liabilities | $618.66K |
| Noncurrent Liabilities | $595.00K |
| Equity | $16.85M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $16.85M |
| Liabilities And Equity | $21.08M |
| Net Cash Flow From Operating Activities | -$25.62M |
| Net Cash Flow From Operating Activities, Continuing | -$25.62M |
| Net Cash Flow From Investing Activities | -$8.98M |
| Net Cash Flow From Investing Activities, Continuing | -$8.98M |
| Net Cash Flow From Financing Activities | $34.60M |
| Net Cash Flow From Financing Activities, Continuing | $34.60M |
| Net Cash Flow | $0.00 |
| Net Cash Flow, Continuing | $0.00 |
| Comprehensive Income/Loss | -$28.85M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$28.85M |
| Other Comprehensive Income/Loss | $0.00 |